NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

We are at 307 from validation, and prior year backlogs have been completely eliminated, but whatever.

Elafibranor was approved by the MHRA on October 4, approximately 312 days after the MAA was validated.

MHRA has approved elafibranor (Iqirvo) on 04 October 2024.

MHRA has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease known as primary biliary cholangitis (PBC).

.
https://www.gov.uk/government/news/elafibranor-approved-as-first-medicine-to-treat-adults-with-a-rare-liver-disease-known-as-primary-biliary-cholangitis

The MAA for elafibranor was validated around november 27, 2023.